 Elaine Lam
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 29 | 2023 | 174 | 6.750 |
Why?
| | Kidney Neoplasms | 32 | 2023 | 334 | 6.380 |
Why?
| | Prostatic Neoplasms | 13 | 2023 | 940 | 3.340 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 60 | 1.710 |
Why?
| | Antineoplastic Agents | 13 | 2023 | 1974 | 1.400 |
Why?
| | Prostate-Specific Antigen | 4 | 2023 | 156 | 1.340 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 1390 | 1.170 |
Why?
| | Neoplasms | 10 | 2023 | 2179 | 1.170 |
Why?
| | Protein Kinase Inhibitors | 11 | 2021 | 811 | 1.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2023 | 667 | 1.070 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 95 | 1.070 |
Why?
| | Seminoma | 2 | 2021 | 17 | 0.930 |
Why?
| | Carcinoma, Medullary | 2 | 2013 | 14 | 0.850 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 23 | 0.800 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 156 | 0.780 |
Why?
| | Teratoma | 1 | 2021 | 92 | 0.760 |
Why?
| | Pneumocystis carinii | 1 | 2020 | 7 | 0.750 |
Why?
| | Spinal Cord Compression | 1 | 2020 | 18 | 0.740 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2020 | 25 | 0.740 |
Why?
| | Male | 51 | 2023 | 57801 | 0.730 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 37 | 0.730 |
Why?
| | Aged | 29 | 2023 | 19657 | 0.720 |
Why?
| | Euterpe | 1 | 2018 | 6 | 0.670 |
Why?
| | Pyrazoles | 3 | 2022 | 363 | 0.650 |
Why?
| | TWEAK Receptor | 1 | 2017 | 5 | 0.630 |
Why?
| | Prednisone | 3 | 2020 | 235 | 0.630 |
Why?
| | Sulfonamides | 3 | 2015 | 445 | 0.620 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.600 |
Why?
| | Humans | 69 | 2023 | 118972 | 0.600 |
Why?
| | Plant Extracts | 1 | 2018 | 165 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 900 | 0.580 |
Why?
| | Pyridines | 4 | 2021 | 440 | 0.570 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 521 | 0.560 |
Why?
| | Brain Neoplasms | 2 | 2021 | 1022 | 0.560 |
Why?
| | Neoplasm Metastasis | 9 | 2020 | 544 | 0.560 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2015 | 143 | 0.560 |
Why?
| | Middle Aged | 30 | 2023 | 27617 | 0.550 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 76 | 0.520 |
Why?
| | Paclitaxel | 3 | 2022 | 195 | 0.500 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 3 | 2022 | 41 | 0.490 |
Why?
| | Interleukin-2 | 2 | 2014 | 416 | 0.480 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.470 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1284 | 0.470 |
Why?
| | Biomarkers, Tumor | 5 | 2016 | 1059 | 0.450 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2023 | 58 | 0.450 |
Why?
| | Retrospective Studies | 16 | 2023 | 12978 | 0.420 |
Why?
| | Epothilones | 1 | 2011 | 1 | 0.420 |
Why?
| | Androgen Antagonists | 3 | 2020 | 70 | 0.410 |
Why?
| | Angiomyolipoma | 1 | 2011 | 18 | 0.410 |
Why?
| | Deoxycytidine | 2 | 2010 | 136 | 0.400 |
Why?
| | Multicenter Studies as Topic | 1 | 2012 | 253 | 0.400 |
Why?
| | Anilides | 4 | 2021 | 69 | 0.390 |
Why?
| | Treatment Outcome | 14 | 2022 | 9342 | 0.380 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2023 | 211 | 0.380 |
Why?
| | Benzenesulfonates | 1 | 2010 | 23 | 0.370 |
Why?
| | Suramin | 1 | 2010 | 6 | 0.370 |
Why?
| | Patient Reported Outcome Measures | 3 | 2020 | 252 | 0.350 |
Why?
| | Aged, 80 and over | 11 | 2020 | 6561 | 0.350 |
Why?
| | Radiosurgery | 3 | 2019 | 318 | 0.350 |
Why?
| | Maximum Tolerated Dose | 6 | 2022 | 185 | 0.350 |
Why?
| | Fluorouracil | 1 | 2008 | 151 | 0.320 |
Why?
| | Bone Neoplasms | 2 | 2023 | 199 | 0.310 |
Why?
| | Neoplasm Staging | 7 | 2017 | 1223 | 0.300 |
Why?
| | Quinazolines | 1 | 2008 | 245 | 0.300 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2013 | 360 | 0.300 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 278 | 0.290 |
Why?
| | Adult | 20 | 2022 | 31512 | 0.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 968 | 0.280 |
Why?
| | Lung Neoplasms | 3 | 2020 | 2220 | 0.280 |
Why?
| | Drug Administration Schedule | 3 | 2021 | 736 | 0.270 |
Why?
| | Prognosis | 5 | 2023 | 3443 | 0.270 |
Why?
| | Sulfones | 2 | 2017 | 98 | 0.260 |
Why?
| | Phenylurea Compounds | 4 | 2016 | 85 | 0.260 |
Why?
| | Female | 25 | 2023 | 61564 | 0.250 |
Why?
| | Ipilimumab | 2 | 2021 | 29 | 0.240 |
Why?
| | Benzoxazoles | 2 | 2022 | 16 | 0.240 |
Why?
| | Taxoids | 2 | 2017 | 98 | 0.230 |
Why?
| | Platinum | 1 | 2023 | 38 | 0.230 |
Why?
| | Bevacizumab | 2 | 2020 | 124 | 0.220 |
Why?
| | Disease Progression | 2 | 2021 | 2490 | 0.220 |
Why?
| | Pyrimidines | 3 | 2022 | 382 | 0.220 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 37 | 0.200 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 20 | 0.200 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 103 | 0.200 |
Why?
| | Celecoxib | 2 | 2012 | 38 | 0.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 341 | 0.190 |
Why?
| | Nephrectomy | 3 | 2023 | 162 | 0.190 |
Why?
| | Carboplatin | 1 | 2021 | 142 | 0.190 |
Why?
| | Syndrome | 1 | 2021 | 344 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 420 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1166 | 0.180 |
Why?
| | Urologic Neoplasms | 1 | 2020 | 25 | 0.180 |
Why?
| | Azepines | 1 | 2020 | 74 | 0.180 |
Why?
| | Thrombosis | 1 | 2023 | 309 | 0.180 |
Why?
| | Antiemetics | 1 | 2020 | 34 | 0.180 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 368 | 0.180 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 35 | 0.180 |
Why?
| | Homologous Recombination | 1 | 2019 | 22 | 0.180 |
Why?
| | Liver Neoplasms | 1 | 2023 | 527 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2020 | 287 | 0.170 |
Why?
| | Morpholines | 1 | 2020 | 106 | 0.170 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2019 | 71 | 0.170 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.170 |
Why?
| | Disease-Free Survival | 4 | 2016 | 649 | 0.170 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 83 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 4 | 2016 | 842 | 0.160 |
Why?
| | Indans | 1 | 2017 | 9 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 62 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 554 | 0.160 |
Why?
| | Interferon beta-1b | 1 | 2017 | 2 | 0.160 |
Why?
| | Immunotherapy | 4 | 2023 | 493 | 0.160 |
Why?
| | Niacinamide | 3 | 2016 | 70 | 0.160 |
Why?
| | Proton Therapy | 1 | 2017 | 10 | 0.150 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 2851 | 0.150 |
Why?
| | Nanoparticles | 1 | 2021 | 325 | 0.150 |
Why?
| | Administration, Oral | 3 | 2022 | 756 | 0.150 |
Why?
| | Erythrocytes, Abnormal | 1 | 2016 | 16 | 0.150 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 68 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 398 | 0.140 |
Why?
| | Hematologic Diseases | 1 | 2016 | 60 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2022 | 1945 | 0.140 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.140 |
Why?
| | Indazoles | 2 | 2015 | 60 | 0.140 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 219 | 0.140 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 2015 | 35 | 0.140 |
Why?
| | Fatigue | 2 | 2022 | 297 | 0.140 |
Why?
| | Pyrroles | 1 | 2016 | 191 | 0.130 |
Why?
| | Angiopoietin-1 | 1 | 2015 | 10 | 0.130 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 13 | 0.130 |
Why?
| | Receptor, IGF Type 1 | 1 | 2015 | 59 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3174 | 0.130 |
Why?
| | Imidazoles | 2 | 2015 | 232 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2015 | 133 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 237 | 0.130 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 93 | 0.130 |
Why?
| | Radiation Tolerance | 1 | 2015 | 98 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1440 | 0.120 |
Why?
| | Indoles | 1 | 2016 | 316 | 0.120 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 103 | 0.120 |
Why?
| | Patient Satisfaction | 1 | 2017 | 610 | 0.110 |
Why?
| | Prostatectomy | 1 | 2013 | 100 | 0.110 |
Why?
| | Glycine | 1 | 2014 | 162 | 0.110 |
Why?
| | Multiple Sclerosis | 1 | 2017 | 384 | 0.110 |
Why?
| | Quinolines | 1 | 2013 | 128 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 653 | 0.110 |
Why?
| | Glomerular Filtration Rate | 1 | 2015 | 683 | 0.100 |
Why?
| | Tubulin Modulators | 1 | 2011 | 10 | 0.100 |
Why?
| | Metabolic Clearance Rate | 1 | 2011 | 113 | 0.100 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 333 | 0.100 |
Why?
| | Arthralgia | 1 | 2011 | 51 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 969 | 0.100 |
Why?
| | Area Under Curve | 1 | 2011 | 296 | 0.100 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 104 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1510 | 0.090 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2011 | 122 | 0.090 |
Why?
| | Cohort Studies | 4 | 2021 | 5116 | 0.090 |
Why?
| | Survival Rate | 3 | 2020 | 1720 | 0.090 |
Why?
| | Diarrhea | 1 | 2011 | 181 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2010 | 25 | 0.090 |
Why?
| | Molecular Structure | 1 | 2011 | 459 | 0.090 |
Why?
| | Biopsy | 1 | 2013 | 1079 | 0.090 |
Why?
| | Nomograms | 1 | 2010 | 48 | 0.090 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2010 | 189 | 0.090 |
Why?
| | Drug Synergism | 1 | 2010 | 339 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.090 |
Why?
| | Quality of Life | 1 | 2020 | 2366 | 0.090 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 380 | 0.080 |
Why?
| | Capecitabine | 1 | 2008 | 46 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 298 | 0.080 |
Why?
| | Melanoma | 1 | 2014 | 664 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2436 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4596 | 0.070 |
Why?
| | Risk | 1 | 2008 | 853 | 0.070 |
Why?
| | Risk Factors | 2 | 2020 | 9000 | 0.070 |
Why?
| | Prospective Studies | 3 | 2021 | 6471 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 10793 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 1798 | 0.050 |
Why?
| | Disease Management | 2 | 2017 | 571 | 0.050 |
Why?
| | Cisplatin | 1 | 2023 | 271 | 0.050 |
Why?
| | Nephritis, Interstitial | 1 | 2020 | 15 | 0.050 |
Why?
| | International Agencies | 1 | 2020 | 29 | 0.050 |
Why?
| | Aurora Kinase A | 1 | 2020 | 52 | 0.050 |
Why?
| | Drug Evaluation | 1 | 2020 | 81 | 0.050 |
Why?
| | Lymphocytes | 1 | 2022 | 347 | 0.050 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 59 | 0.050 |
Why?
| | Medical Oncology | 1 | 2022 | 229 | 0.040 |
Why?
| | Nausea | 1 | 2020 | 107 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 3457 | 0.040 |
Why?
| | Vomiting | 1 | 2020 | 123 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6412 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 307 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 598 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 144 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 245 | 0.040 |
Why?
| | United States | 2 | 2017 | 12555 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 389 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 740 | 0.040 |
Why?
| | Retreatment | 1 | 2017 | 71 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 965 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 422 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 278 | 0.040 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 29 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 229 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 465 | 0.040 |
Why?
| | Neutrophils | 1 | 2022 | 1233 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 245 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 28 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 34 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 671 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2015 | 14 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 30 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 164 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 258 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 219 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 120 | 0.030 |
Why?
| | Organ Size | 1 | 2015 | 460 | 0.030 |
Why?
| | Postoperative Period | 1 | 2015 | 309 | 0.030 |
Why?
| | Radiotherapy | 1 | 2015 | 187 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 155 | 0.030 |
Why?
| | Demography | 1 | 2015 | 274 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 975 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 128 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 43 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 352 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2015 | 193 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2513 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 556 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2015 | 569 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1125 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1047 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2016 | 1687 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3588 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2014 | 359 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 356 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 618 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 827 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 565 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1901 | 0.020 |
Why?
| | Animals | 2 | 2020 | 33381 | 0.020 |
Why?
| | Mice | 1 | 2020 | 15520 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 18480 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 4709 | 0.010 |
Why?
|
|
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|